In a genome-wide screen of 684 cancer cell lines, we identified homozygous intragenic microdeletions involving genes encoding components of the apical-basal cell polarity complexes. Among these, PARD3 is disrupted in cell lines and primary tumors from squamous carcinomas and glioblastomas. Reconstituting PARD3 expression in both cell types restores tight junctions and retards contact-dependent proliferation. Searching specifically for small intragenic microdeletions using high-resolution genomic arrays may be complementary to other genomic deletion screens and resequencing efforts in identifying new tumor suppressor genes. Cancer Res; 70(6); 2158-64. ©2010 AACR.
Introduction
Classic tumor suppressor gene discovery involved loss-ofheterozygosity screens, followed by detailed mapping of tumor-dependent allelic losses (1), whereas subsequent efforts used genome-wide PCR-based methods to detect rare homozygous deletions (2, 3) , array-based hybridization technologies (4, 5) , and, most recently, whole-genome exon resequencing (6, 7) . However, the complexity of these efforts has limited the number of tumors that can be screened by each method, a critical consideration because the recurrence of a gene-targeting event across different cancers is key to distinguishing driver from passenger mutations.
Here, we performed a high-resolution array-based gene copy number analysis of 684 cancer cell lines, with the goal of identifying rare homozygous deletions across a broad panel of diverse cancer types. Although initial arrays based on BACs or cDNAs contained relatively sparse genomic probes, the advent of oligonucleotide arrays with every increasing probe density has paved the way for simultaneously interrogating large numbers of tumors at increased resolution for discrete regions of genomic loss (8, 9) . However, genomic instability in epithelial cancers has complicated attempts at finding recurrent deletions using copy number screens, leading to algorithms that readily reveal large, frequent amplifications and deletions, possibly at the expense of focal or less frequent variation in allelic dosage (10, 11) . In contrast, we reasoned that the use of a very large cancer cell line panel would enable a focused screen for small intragenic deletions, and that recurrence of such focal deletions across different cancers would serve as evidence of functional significance. In addition, the primary screen provides the key target cells in which to test reconstitution of the deleted gene. Array hybridization. Sample processing for genomic DNA, complexity reduction, amplification, purification, labeling, and hybridization to GeneChip Human Mapping 250K Sty Arrays 10 were done as described in the Affymetrix GeneChip Human Mapping 500K assay manual (P/N 701930 Rev. 2). Genomic DNA samples from six EBV-transformed B-lymphocyte cell lines were included as normal controls for copy number calculations (Coriell Institute for Medical Research, Camden, NJ). Array hybridization, data acquisition, and analysis for Agilent Human 105K oligonucleotide arrays were based on published methods (12) . Additional methods describing preparation of nucleic acid and data acquisition and initial processing are available in Supplementary Data.
Materials and Methods
Copy number analysis and identification of candidate tumor suppressor loci. The method for identifying homozygous deletions is outlined in Supplementary Fig. S1B and described in detail in Supplementary Data. Briefly, after calculation of copy number for each SNP probe using dCHIP, 11 a copy number threshold equal to <0.3 was applied to select candidate deleted regions (this threshold was found empirically to correctly capture common tumor suppressor genes known to be inactivated by deletion, e.g., CKDN2A/B and PTEN; Supplementary Table S2C; Supplementary Fig. S2 ). Next, the boundaries of each deletion were adjusted such that deleted probes occurring within 0.1 Mb of each other in the same sample were initially considered as a single deleted region. Then, deletions that did not disrupt exons of protein-coding genes (using the March 2004 hg17 human reference sequence) and were not recurrent were eliminated. This left 706 recurrent deletions constituting 211 unique genes (from 2 to 145 deletions per gene; Supplementary Table S2 ). To select genes for further analysis, we focused on genes disrupted by deletion in multiple samples (see Supplementary Data for calculation of the number of recurrences likely to be significant), as well as small deletions containing genes not clearly implicated in tumorigenesis and without extensive copy number polymorphisms (according to the Database of Genomic Variants 12 ). Among these, PARD3 was selected for further analysis.
PCR-based exon resequencing and reverse transcription-PCR. See Supplementary Data.
Fluorescence in situ hybridization. All BAC probes were obtained from BAC/PAC Resources (Children's Hospital, Oakland, CA). PARD3 gene copy number was determined by two-color fluorescence in situ hybridization (FISH) on 5-μm-thick sections following published protocols (13) . Images were acquired using an Olympus BX61 fluorescent microscope equipped with a charge-coupled device camera, and analysis was done with Genus software (Applied Imaging). At least 100 nuclei were scored for each sample. Nontumor tissue samples were used as controls (Cybrdi, Inc.).
DNA and shRNA constructs and lentivirus expression. The cDNA for PARD3 was generously provided by Ian Macara (University of Virginia, Charlotsville, VA). See Supplementary Data for additional details on cDNA and shRNA vector construction and expression.
Immunoblotting and immunofluorescence. See Supplementary Data.
Growth assays. Cells were plated at 50,000 to 100,000 per well in triplicate in six-well plates. At each time point, cells were detached with trypsin, stained with 1:10 dilution of 0.1% trypan blue, and counted using a Cellometer Auto T4 (Nexcelom Bioscience LLC). Medium was refreshed on the remaining wells every 3 d.
Results
Analysis of 684 specimens with 250,000 SNP probes identified 11,328 regions with a reduction in copy number consistent with a homozygous deletion (<0.3; Supplementary Fig.  S1 ; Supplementary Table S1 ). Filtering for overlap with exons of protein-coding genes and involvement of the candidate gene by at least one other deletion in an unrelated cancer cell line produced 211 genes identified as being inactivated by focal, recurrent homozygous deletions. These included 9 bona fide tumor suppressor genes (thereby validating the approach), 6 putative tumor suppressor genes located within highly polymorphic regions of the genome, and 196 novel candidate genes (Supplementary Table S2 ; Supplementary  Fig. S2 ). Among these are five genes (PARD6G, PARD3, PARD3B, MPDZ, and DLG2) that encode components of the PAR, SCRB, and CRB protein complexes implicated in apicalbasal cell polarity (Table 1; ref. 14) . The most commonly targeted polarity gene, PARD3 (chromosomal locus 10p11.21), was selected for detailed analysis.
Microdeletions in PARD3 were evident in 8 samples, removing 2 to 23 of the 25 coding exons, without affecting neighboring genes (Figs. 1 and 2A) . Remarkably, PARD3 deletions were limited to two very distinct types of cancer: squamous carcinomas [2 of 20 esophagus (SCCE), 4 of 35 head and neck (SCCHN), and 1 of 14 lung] and glioblastoma (GBM; 1 of 16). All deletions were confirmed by PCR amplification of genomic DNA (Fig. 2B) . Reverse transcription-PCR (RT-PCR), nucleotide sequencing, and immunoblot analysis showed absence of wild-type PARD3 mRNA and fusion of the deletion-flanking exons, with frameshift and loss of detectable protein expression ( Fig. 2C; Supplementary Fig. S3 ).
To extend the cell line analysis to primary tumor specimens, we analyzed 21 SCCHN, 29 SCCE, and 43 GBM. Somatic, intragenic PARD3 mutations were observed in four tumors: two homozygous deletions (GBM and SCCE), one heterozygous deletion (SCCHN), and one splice-site mutation (GBM; Fig. 3; Supplementary Fig. S4 ). Analysis of the SCCHN with a heterozygous deletion revealed a truncated PARD3 mRNA leading to a frameshift and stop codon (Fig. 3A) . Analysis of the GBM with a splice-site mutation (this tumor had loss of the other chromosome 10) showed aberrant mRNA splicing, removing regions encoding PDZ domains 1 and 2 that are critical for effector binding (Figs. 1 and 3C ). In addition to these definitive mutations, previously unreported missense mutations were identified in four cases (Supplementary Fig. S5A ). The combined mutation analysis of cell lines and primary tumors suggests that definitive PARD3 alterations occur in up to 9% of SCCHN, 6% of SCCE, and 5% of GBMs ( Supplementary  Fig. S5B ).
The identification of PARD3 deletions in cancer cell lines made it possible to test the consequences of reexpression of the wild-type cDNA (Fig. 4A) . Both squamous cancer and GBM cells with PARD3 deletions showed reduced localization of ZO-1 to regions of cell-cell contact ( Fig. 4B and C) . Reconstitution of PARD3 expression resulted in relocalization of ZO-1 to appropriate intercellular junctions ( Fig. 4B and C) . The consequence of PARD3 reexpression on cell proliferation seemed to be specific to intercellular contact, in that PARD3-defective or reconstituted cells proliferated at comparable rates when seeded at low density, but a clear enhancement of PARD3-null cell proliferation emerged once cell density allowed for cell-cell contact (Fig. 4D) . shRNA-mediated knockdown of PARD3 in other cancer cells with a wild-type endogenous gene resulted in reduced localization of ZO-1 to cell-cell contacts and enhanced proliferation (Supplementary Supplementary Fig. S7 ). There was no consistent effect of PARD3 reexpression on markers of squamous differentiation ( Supplementary Fig. S8 ).
Discussion
PARD3 is thought to be a master regulator of apical-basal cell polarity, a process that has been indirectly implicated in tumorigenesis (15, 16) . Recently, SCRIB (also known as Scribble) was proposed as a tumor suppressor by virtue of its mislocalization in human breast cancers (17) . However, inactivating mutations in SCRIB have not been identified, and it is possible that mutational inactivation of PARD3 (and potentially other polarity complex family members) provides a genetic mechanism that explains dysregulation of cell polarity in a subset of human cancers. While this Research.
on April 14, 2017. © 2010 American Association for Cancer cancerres.aacrjournals.org Downloaded from article was in preparation, Zen and colleagues (18) reported finding PARD3 deletions in the SCCE cell lines also described here (e.g., KYSE-30 and KYSE-270). As shown in our two studies, loss of PARD3 in SCCE cells leads to abnormal cellular contacts, consistent with disruption of the PAR polarity complex. The apparent tissue specificity of PARD3 deletions uncovered in our study, affecting both diverse squamous epithelial cancers and GBMs, highlights a somewhat unexpected parallel role for the PAR complex in these very distinct cell types. The loss of tight junctions may permit contact-inhibited cells to loosen from neighboring cells and proliferate. Notably, genomic losses affecting chromosome 10p have been shown in primary GBMs, suggesting the presence of a novel tumor suppressor(s) (in addition to PTEN on 10q; ref. 19) .
The strategy that we used to identify targeted homozygous deletions is complementary to that of ongoing cancer genome sequencing efforts. Cell line analysis offers the advantage of a homogeneous tumor cell population free of contaminating stromal cells that could mask deletions. However, to rule out potential cell culture-related genetic events, it is critical to show the presence of inactivating mutations in primary tumor samples. As we have shown for PARD3 and potentially other tumor suppressors, deletion of one or a few exons can have dramatic consequences for gene expression. It is generally assumed that tumor suppressor genes are more frequently targeted by point mutations than by deletion events, although for PARD3, as well as other well-established tumor suppressor genes such as CDKN2A/B, chromosome deletions seem to be predominant. Consistent with this observation, PARD3 mutations were not identified in a recent genome resequencing analysis of 22 human GBMs (20) . Moreover, the small homozygous PARD3 deletions also went undetected in other gene copy number screens using oligonucleotide arrays, perhaps due to primary tumor heterogeneity or algorithms that filter the deleted segments by size and frequency (8) . As the density of genomic probes increases, optimizing these approaches to allow detection of focal homozygous deletions, and using a very large panel of cancer cell lines to increase the chance of detecting recurrent lesions across diverse cancer types, thus offers a potentially important tool for new cancer gene discovery.
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